|
1
|
Liu Y, Han X, Yu Y, Ding Y, Ni C, Liu W,
Hou X, Li Z, Hou J, Shen D, et al: A genetic polymorphism affects
the risk and prognosis of renal cell carcinoma: Association with
follistatin-like protein 1 expression. Sci Rep. 6:266892016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Garcia JA, Cowey CL and Godley PA: Renal
cell carcinoma. Curr Opin Oncol. 21:266–271. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Patard JJ, Leray E, Rioux-Leclercq N,
Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani
W, Abbou CC, et al: Prognostic value of histologic subtypes in
renal cell carcinoma: A multicenter experience. J Clin Oncol.
23:2763–2771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nerich V, Hugues M, Paillard MJ, Borowski
L, Nai T, Stein U, Nguyen Tan Hon T, Montcuquet P, Maurina T,
Mouillet G, et al: Clinical impact of targeted therapies in
patients with metastatic clear-cell renal cell carcinoma. Onco
Targets Ther. 7:365–374. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu D, Li M, Wang L, Zhou Y, Zhou J, Pan H
and Qu P: microRNA145 inhibits cell proliferation, migration and
invasion by targeting matrix metallopeptidase-11 in renal cell
carcinoma. Mol Med Rep. 10:393–398. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Crispen PL, Breau RH, Allmer C, Lohse CM,
Cheville JC, Leibovich BC and Blute ML: Lymph node dissection at
the time of radical nephrectomy for high-risk clear cell renal cell
carcinoma: Indications and recommendations for surgical templates.
Eur Urol. 59:18–23. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Flanigan RC, Campbell SC, Clark JI and
Picken MM: Metastatic renal cell carcinoma. Curr Treat Options
Oncol. 4:385–390. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Breda A, Konijeti R and Lam JS: Patterns
of recurrence and surveillance strategies for renal cell carcinoma
following surgical resection. Expert Rev Anticancer Ther.
7:847–862. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang YQ and Chen J: Predictive role of
vascular endothelial growth factor polymorphisms in the survival of
renal cell carcinoma patients. Genet Mol Res. 13:5011–5017. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bryzgunova OE, Konoshenko MY and Laktionov
PP: MicroRNA-guided gene expression in prostate cancer: Literature
and database overview. J Gene Med. 20:e30162018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pratap P, Raza ST, Abbas S and Mahdi F:
MicroRNA-associated carcinogenesis in lung carcinoma. J Cancer Res
Ther. 14:249–254. 2018.PubMed/NCBI
|
|
15
|
Vannini I, Fanini F and Fabbri M: Emerging
roles of microRNAs in cancer. Curr Opin Genet Dev. 48:128–133.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun X, Lou L, Zhong K and Wan L:
MicroRNA-451 regulates chemoresistance in renal cell carcinoma by
targeting ATF-2 gene. Exp Biol Med (Maywood). 242:1299–1305. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiao W, Lou N, Ruan H, Bao L, Xiong Z,
Yuan C, Tong J, Xu G, Zhou Y, Qu Y, et al: Mir-144-3p promotes cell
proliferation, metastasis, sunitinib resistance in clear cell renal
cell carcinoma by downregulating ARID1A. Cell Physiol Biochem.
43:2420–2433. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang F, Ma J, Tang Q, Zhang W, Fu Q, Sun
J, Wang H and Song B: MicroRNA-543 promotes the proliferation and
invasion of clear cell renal cell carcinoma cells by targeting
Krüppel-like factor 6. Biomed Pharmacother. 97:616–623. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He YH, Chen C and Shi Z: The biological
roles and clinical implications of microRNAs in clear cell renal
cell carcinoma. J Cell Physiol. 233:4458–4465. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jaswani P, Prakash S, Dhar A, Sharma RK,
Prasad N and Agrawal S: MicroRNAs involvement in renal
pathophysiology: A bird's eye view. Indian J Nephrol. 27:337–341.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ellinger J, Gevensleben H, Muller SC and
Dietrich D: The emerging role of non-coding circulating RNA as a
biomarker in renal cell carcinoma. Expert Rev Mol Diagn.
16:1059–1065. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hong L, Wang Y, Chen W and Yang S:
MicroRNA-508 suppresses epithelial-mesenchymal transition,
migration, and invasion of ovarian cancer cells through the
MAPK1/ERK signaling pathway. J Cell Biochem. 119:7431–7440. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yan TT, Ren LL, Shen CQ, Wang ZH, Yu YN,
Liang Q, Tang JY, Chen YX, Sun DF, Zgodzinski W, et al: miR-508
defines the stem-like/mesenchymal subtype in colorectal cancer.
Cancer Res. 78:1751–1765. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin C, Liu A, Zhu J, Zhang X, Wu G, Ren P,
Wu J, Li M, Li J and Song L: miR-508 sustains phosphoinositide
signalling and promotes aggressive phenotype of oesophageal
squamous cell carcinoma. Nat Commun. 5:46202014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhai Q, Zhou L, Zhao C, Wan J, Yu Z, Guo
X, Qin J, Chen J and Lu R: Identification of miR-508-3p and
miR-509-3p that are associated with cell invasion and migration and
involved in the apoptosis of renal cell carcinoma. Biochem Biophys
Res Commun. 419:621–626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fujii N, Hirata H, Ueno K, Mori J, Oka S,
Shimizu K, Kawai Y, Inoue R, Yamamoto Y, Matsumoto H, et al:
Extracellular miR-224 as a prognostic marker for clear cell renal
cell carcinoma. Oncotarget. 8:109877–109888. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang S, Guo Z, Xu J, Wang J, Zhang J, Cui
L, Zhang H, Liu Y and Bai Y: miR-502-mediated histone
methyltransferase SET8 expression is associated with clear cell
renal cell carcinoma risk. Oncol Lett. 14:7131–7138.
2017.PubMed/NCBI
|
|
29
|
Chen J, Shu Y, Yu Q and Shen W:
MicroRNA-645 promotes cell metastasis and proliferation of renal
clear cell carcinoma by targeting GK5. Eur Rev Med Pharmacol Sci.
21:4557–4565. 2017.PubMed/NCBI
|
|
30
|
Ding D, Zhang Y, Wen L, Fu J, Bai X, Fan
Y, Lin Y, Dai H, Li Q, Zhang Y and An R: MiR-367 regulates cell
proliferation and metastasis by targeting metastasis-associated
protein 3 (MTA3) in clear-cell renal cell carcinoma. Oncotarget.
8:63084–63095. 2017.PubMed/NCBI
|
|
31
|
Fan Y, Ma X, Li H, Gao Y, Huang Q, Zhang
Y, Bao X, Du Q, Luo G, Liu K, et al: miR-122 promotes metastasis of
clear-cell renal cell carcinoma by downregulating Dicer. Int J
Cancer. 142:547–560. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu F, Wu L, Wang A, Xu Y, Luo X, Liu X,
Hua Y, Zhang D, Wu S, Lin T, et al: MicroRNA-138 attenuates
epithelial-to-mesenchymal transition by targeting SOX4 in clear
cell renal cell carcinoma. Am J Transl Res. 9:3611–3622.
2017.PubMed/NCBI
|
|
33
|
Wang C, Cai L, Liu J, Wang G, Li H, Wang
X, Xu W, Ren M, Feng L, Liu P and Zhang C: MicroRNA-30a-5p inhibits
the growth of renal cell carcinoma by modulating GRP78 expression.
Cell Physiol Biochem. 43:2405–2419. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jones KB, Salah Z, Del Mare S, Galasso M,
Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, et
al: miRNA signatures associate with pathogenesis and progression of
osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shen A, Zhang Y, Yang H, Xu R and Huang G:
Overexpression of ZEB1 relates to metastasis and invasion in
osteosarcoma. J Surg Oncol. 105:830–834. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Larsen JE, Nathan V, Osborne JK, Farrow
RK, Deb D, Sullivan JP, Dospoy PD, Augustyn A, Hight SK, Sato M, et
al: ZEB1 drives epithelial-to-mesenchymal transition in lung
cancer. J Clin Invest. 126:3219–3235. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jia B, Liu H, Kong Q and Li B:
Overexpression of ZEB1 associated with metastasis and invasion in
patients with gastric carcinoma. Mol Cell Biochem. 366:223–229.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang GJ, Zhou T, Tian HP, Liu ZL and Xia
SS: High expression of ZEB1 correlates with liver metastasis and
poor prognosis in colorectal cancer. Oncol Lett. 5:564–568. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Singh M, Spoelstra NS, Jean A, Howe E,
Torkko KC, Clark HR, Darling DS, Shroyer KR, Horwitz KB, Broaddus
RR and Richer JK: ZEB1 expression in type I vs. type II endometrial
cancers: A marker of aggressive disease. Mod Pathol. 21:912–923.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Harb OA, Elfeky MA, El Shafaay BS, Taha
HF, Osman G, Harera IS, Gertallah LM, Abdelmonem DM and Embaby A:
SPOP, ZEB-1 and E-cadherin expression in clear cell renal cell
carcinoma (cc-RCC): Clinicopathological and prognostic
significance. Pathophysiology. 25:335–345. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang S, Hong Z, Chai Y, Liu Z, Du Y, Li Q
and Liu Q: CSN5 promotes renal cell carcinoma metastasis and EMT by
inhibiting ZEB1 degradation. Biochem Biophys Res Commun.
488:101–108. 2017. View Article : Google Scholar : PubMed/NCBI
|
